Clinical Trial Update: A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer

View source ↗

Summary

A clinical trial evaluating nivolumab for early-stage esophageal or gastroesophageal junction cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Carcinoma
• Gastroesophageal Junction Carcinoma

Drugs mentioned

• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Esophageal Carcinoma, Gastroesophageal Junction Carcinoma | Status: TERMINATED